DOCSLIB.ORG

Perkinelmer Genomics to Request the Saliva Swab Collection Kit for Patients That Cannot Provide a Blood Sample As Whole Blood Is the Preferred Sample

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Perkinelmer Genomics to Request the Saliva Swab Collection Kit for Patients That Cannot Provide a Blood Sample As Whole Blood Is the Preferred Sample STAT Eye Disorders Comprehensive Panel Test Code D4306F Test Summary This test analyzes 211 genes that have been associated with ocular disorders with results in 7-10 days Turn-Around-Time (TAT)* 7 - 10 days Acceptable Sample Types Whole Blood (EDTA) (Preferred sample type) DNA, Isolated Dried Blood Spots Saliva Acceptable Billing Types Self (patient) Payment Institutional Billing Indications for Testing Individuals with an eye disease suspected to be genetic in origin Individuals with a family history of eye disease Individuals suspected to have a syndrome associated with an eye disease Test Description This panel analyzes 211 genes that have been associated with ocular disorders. Both sequencing and deletion/duplication (CNV) analysis will be performed on the coding regions of all genes included (unless otherwise marked). All analysis is performed utilizing Next Generation Sequencing (NGS) technology. CNV analysis is designed to detect the majority of deletions and duplications of three exons or greater in size. Smaller CNV events may also be detected and reported, but additional follow-up testing is recommended if a smaller CNV is suspected. All variants are classified according to ACMG guidelines. Condition Description Diseases associated with this panel include microphtalmia, anophthalmia, coloboma, progressive external ophthalmoplegia, optic nerve atrophy, retinal dystrophies, retinitis pigementosa, macular degeneration, flecked-retinal disorders, Usher syndrome, albinsm, Aloprt syndrome, Bardet Biedl syndrome, pulmonary fibrosis, and Hermansky-Pudlak syndrome. Genes ABCA4, ABHD12, ADAM9, ADGRV1, AHI1, AIPL1, ALMS1, ARL13B, ARL6, ATP13A2, B3GLCT, BBS1, BBS10, BBS12, BBS2, BBS4, BBS5, BBS7, BBS9, BCOR, BEST1, BMP4, C10orf11, C1QTNF5, C2orf71, C5orf42, C8orf37, CA4, CABP4, CACNA1F, CACNA2D4, CC2D2A, CDH23, CDH3, CDHR1, CEP290, CEP41, CERKL, CHM, CIB2, CLN3, CLN5, CLN6, CLN8, CLRN1, CNGA1, CNGA3, CNGB1, CNGB3, CNNM4, COL11A1, COL11A2, COL2A1, COL4A1, COL9A1, COL9A2, CRB1, CRX, CTSD, CYP1B1, CYP27A1, CYP4V2, DHDDS, EFEMP1, ELOVL4, EYS, FAM161A, FLVCR1, FOXC1, FOXE3, FRAS1, FREM1, FREM2, FSCN2, FZD4, GNAT1, GNAT2, GPR143, GPR179, GRIP1, GRM6, GRN, GUCA1A, GUCA1B, GUCY2D, HARS, HCCS, IDH3B, IMPDH1, IMPG2, INVS, IQCB1, KCNJ13, KCNV2, KCTD7, KIF7, KLHL7, LCA5, LRAT, LRIT3, LRP5, LZTFL1, MAK, MERTK, MFN2, MFRP, MFSD8, MKKS, MKS1, MTTP, MYO7A, MYOC, NDP, NPHP1, NPHP3, NPHP4, NR2E3, NRL, NYX, OAT, OCA2, OCRL, OFD1, OPA1, OPA3, OTX2, PAX6, PCDH15, PDE6A, PDE6B, PDE6C, PDE6G, PDE6H, PEX7, PHYH, PITPNM3, PITX2, PITX3, PLA2G5, PPT1, PRCD, PROM1, PRPF3, PRPF31, PRPF6, PRPF8, PRPH2, RAX2, RBP3, RBP4, RD3, RDH12, RDH5, RGR, RGS9, RGS9BP, RHO, RIMS1, RLBP1, ROM1, RP1, RP2, RP9, RPE65, RPGR, RPGRIP1, RPGRIP1L, RS1, SAG, SDCCAG8, SEMA4A, SLC24A1, SLC24A5, SLC45A2, SMOC1, SNRNP200, SOX2, SPATA7, STRA6, TCTN1, TCTN2, TCTN3, TIMM8A, TIMP3, TMEM126A, TMEM216, TMEM237, TMEM67, TOPORS, TPP1, TRIM32, TRPM1, TSPAN12, TTC21B, TTC8, TULP1, TYR, TYRP1, UNC119, USH1C, USH1G, USH2A, VAX1, VCAN, VSX2, WDPCP, WFS1, WHRN, WT1, ZNF423, ZNF513 250 Industry Drive Pittsburgh, PA 15275 • T 866-354-2910 • F 412-220-0785 www.perkinelmergenomics.com Page 1 of 3 Test Methods and Limitations Sequencing is performed on genomic DNA using an Agilent targeted sequence capture method to enrich for the genes on this panel. Direct sequencing of the amplified captured regions was performed using 2X100bp reads on Illumina next generation sequencing (NGS) systems. A base is considered to have sufficient coverage at 20X and an exon is considered fully covered if all coding bases plus three nucleotides of flanking sequence on either side are covered at 20X or more. Low coverage regions, if any, are limited to ~1% or less of the nucleotides in the test unless a pathogenic variant explaining the phenotype is discovered. A list of these regions is available upon request. Alignment to the human reference genome (hg19) is performed and annotated variants are identified in the targeted region. Variants are called at a minimum coverage of 8X and an alternate allele frequency of 20% or higher. Single nucleotide variants (SNVs) meeting internal quality assessment guidelines are confirmed by Sanger sequence analysis for records after results are reported. Indels and SNVs are confirmed by Sanger sequence analysis before reporting at director discretion. This assay cannot detect variants in regions of the exome that are not covered, such as deep intronic, promoter and enhancer regions, areas containing large numbers of tandem repeats, and variants in mitochondrial DNA. Copy number variation (CNV) analysis is designed to detect deletions and duplications of three exons or more; in some instances, due to the size of the exons or other factors, not all CNVs may be analyzed. This assay is not designed to detect mosaicism; possible cases of mosaicism may be investigated at the discretion of the laboratory director. Primary data analysis is performed using Illumina DRAGEN Bio-IT Platform v.2.03. Secondary and tertiary data analysis is performed using PerkinElmer's internal ODIN v.1.01 software for SNVs and Biodiscovery's NxClinical v.4.3 or Illumina DRAGEN Bio-IT Platform v.2.03 for CNV and absence of heterozygosity (AOH). Genes and/or exons located in pseudogene regions are not covered in this assay. Detailed Sample Requirements Whole Blood (EDTA) (Preferred sample type) Collection Container(s): EDTA (purple top) Collection: Infants (< 2-years): 2 to 3 mL; Children (>2-years): 3 to 5 mL; Older children and adults: 5 to 10 mL Southern Blot Analysis requires 3 mL blood. Sample Condition: Store at ambient temperature. Do not refrigerate or freeze. Shipping: Ship overnight at ambient temperature ensuring receipt within 4-days of collection. SPECIAL INSTRUCTIONS: Clotted or hemolyzed samples are not accepted. DNA, Isolated Collection: Required DNA Quantity by Test Type*: Next Generation Sequencing (NGS): Send >500ng total gDNA @ > 15ng/?L. Please ship samples in 10mM Tris. No EDTA. Sanger Sequencing: Send 5 to 25 micrograms (varies by size of gene). Please contact the laboratory for specificamounts. Non-Sequencing Tests: Send 20 micrograms Array-based Tests: Send 10 micrograms *Required DNA Quality: High molecular weight DNA (>12kb). A260/A280 reading should be >= 1.8. Shipping: Ship overnight at ambient temperature. SPECIAL INSTRUCTIONS: Research Laboratories: DNA extracted in research laboratories is not acceptable. Only under exceptional circumstances (e.g. proband not available) will DNA extracted in a research laboratory be accepted for clinical testing. Additional testing (e.g. of other family members) may be required to confirm results. Laboratories outside the United States: Non-US laboratories are not subject to CLIA regulations and will be reviewed on a case-by-case 250 Industry Drive Pittsburgh, PA 15275 • T 866-354-2910 • F 412-220-0785 www.perkinelmergenomics.com Page 2 of 3 basis. Please call to speak with a laboratory genetic counselor prior to submitting a DNA sample from any non-CLIA certified laboratory. Special Notes: If extracted DNA is submitted, information regarding the method used for extraction should be sent along with the sample. Dried Blood Spots Collection Container(s): Dried blood spot card Collection: Follow kit instructions. Briefly, allow blood to saturate card until indicated areas are filled and blood has soaked through card. Air dry card at ambient temperature for at least 3 hours. NBS: Please contact PKIG to request the StepOne® kit. Gene Sequencing: Please contact PKIG to request the DBS collection kit. Shipping: Follow kit instructions. Double bag and ship overnight at ambient temperature. Saliva Collection Container(s): ORAcollect®•Dx Saliva Swab Collection Kit Collection: Collect saliva in an ORAcollect®•Dx Saliva Swab Collection Kit according to the manufacturer's instructions. Please contact PerkinElmer Genomics to request the saliva swab collection kit for patients that cannot provide a blood sample as whole blood is the preferred sample. Sample Condition: Store at ambient temperature. Do not refrigerate or freeze. Shipping: Ship overnight at ambient temperature. 250 Industry Drive Pittsburgh, PA 15275 • T 866-354-2910 • F 412-220-0785 www.perkinelmergenomics.com Page 3 of 3 Powered by TCPDF (www.tcpdf.org).
Load more

Recommended publications
  • Educational Paper Ciliopathies
    Eur J Pediatr (2012) 171:1285–1300 DOI 10.1007/s00431-011-1553-z REVIEW Educational paper Ciliopathies Carsten Bergmann Received: 11 June 2011 /Accepted: 3 August 2011 /Published online: 7 September 2011 # The Author(s) 2011. This article is published with open access at Springerlink.com Abstract Cilia are antenna-like organelles found on the (NPHP) . Ivemark syndrome . Meckel syndrome (MKS) . surface of most cells. They transduce molecular signals Joubert syndrome (JBTS) . Bardet–Biedl syndrome (BBS) . and facilitate interactions between cells and their Alstrom syndrome . Short-rib polydactyly syndromes . environment. Ciliary dysfunction has been shown to Jeune syndrome (ATD) . Ellis-van Crefeld syndrome (EVC) . underlie a broad range of overlapping, clinically and Sensenbrenner syndrome . Primary ciliary dyskinesia genetically heterogeneous phenotypes, collectively (Kartagener syndrome) . von Hippel-Lindau (VHL) . termed ciliopathies. Literally, all organs can be affected. Tuberous sclerosis (TSC) . Oligogenic inheritance . Modifier. Frequent cilia-related manifestations are (poly)cystic Mutational load kidney disease, retinal degeneration, situs inversus, cardiac defects, polydactyly, other skeletal abnormalities, and defects of the central and peripheral nervous Introduction system, occurring either isolated or as part of syn- dromes. Characterization of ciliopathies and the decisive Defective cellular organelles such as mitochondria, perox- role of primary cilia in signal transduction and cell isomes, and lysosomes are well-known
    [Show full text]
  • Ciliopathiesneuromuscularciliopathies Disorders Disorders Ciliopathiesciliopathies
    NeuromuscularCiliopathiesNeuromuscularCiliopathies Disorders Disorders CiliopathiesCiliopathies AboutAbout EGL EGL Genet Geneticsics EGLEGL Genetics Genetics specializes specializes in ingenetic genetic diagnostic diagnostic testing, testing, with with ne nearlyarly 50 50 years years of of clinical clinical experience experience and and board-certified board-certified labor laboratoryatory directorsdirectors and and genetic genetic counselors counselors reporting reporting out out cases. cases. EGL EGL Genet Geneticsics offers offers a combineda combined 1000 1000 molecular molecular genetics, genetics, biochemical biochemical genetics,genetics, and and cytogenetics cytogenetics tests tests under under one one roof roof and and custom custom test testinging for for all all medically medically relevant relevant genes, genes, for for domestic domestic andand international international clients. clients. EquallyEqually important important to to improving improving patient patient care care through through quality quality genetic genetic testing testing is is the the contribution contribution EGL EGL Genetics Genetics makes makes back back to to thethe scientific scientific and and medical medical communities. communities. EGL EGL Genetics Genetics is is one one of of only only a afew few clinical clinical diagnostic diagnostic laboratories laboratories to to openly openly share share data data withwith the the NCBI NCBI freely freely available available public public database database ClinVar ClinVar (>35,000 (>35,000 variants variants on on >1700 >1700 genes) genes) and and is isalso also the the only only laboratory laboratory with with a a frefree oen olinnlein dea dtabtaabsaes (eE m(EVmCVlaCslas)s,s f)e, afetuatruinrgin ag vaa vraiarniatn ctl acslasisfiscifiactiaotino sne saercahrc ahn adn rde rpeoprot rrte rqeuqeuset sint tinetrefarcfaec, ew, hwichhic fha cfailcitialiteatse rsa praidp id interactiveinteractive curation curation and and reporting reporting of of variants.
    [Show full text]
  • Rare Variant Analysis of Human and Rodent Obesity Genes in Individuals with Severe Childhood Obesity Received: 11 November 2016 Audrey E
    www.nature.com/scientificreports OPEN Rare Variant Analysis of Human and Rodent Obesity Genes in Individuals with Severe Childhood Obesity Received: 11 November 2016 Audrey E. Hendricks1,2, Elena G. Bochukova3,4, Gaëlle Marenne1, Julia M. Keogh3, Neli Accepted: 10 April 2017 Atanassova3, Rebecca Bounds3, Eleanor Wheeler1, Vanisha Mistry3, Elana Henning3, Published: xx xx xxxx Understanding Society Scientific Group*, Antje Körner5,6, Dawn Muddyman1, Shane McCarthy1, Anke Hinney7, Johannes Hebebrand7, Robert A. Scott8, Claudia Langenberg8, Nick J. Wareham8, Praveen Surendran9, Joanna M. Howson9, Adam S. Butterworth9,10, John Danesh1,9,10, EPIC-CVD Consortium*, Børge G Nordestgaard11,12, Sune F Nielsen11,12, Shoaib Afzal11,12, SofiaPa padia3, SofieAshford 3, Sumedha Garg3, Glenn L. Millhauser13, Rafael I. Palomino13, Alexandra Kwasniewska3, Ioanna Tachmazidou1, Stephen O’Rahilly3, Eleftheria Zeggini1, UK10K Consortium*, Inês Barroso1,3 & I. Sadaf Farooqi3 Obesity is a genetically heterogeneous disorder. Using targeted and whole-exome sequencing, we studied 32 human and 87 rodent obesity genes in 2,548 severely obese children and 1,117 controls. We identified 52 variants contributing to obesity in 2% of cases including multiple novel variants in GNAS, which were sometimes found with accelerated growth rather than short stature as described previously. Nominally significant associations were found for rare functional variants inBBS1 , BBS9, GNAS, MKKS, CLOCK and ANGPTL6. The p.S284X variant in ANGPTL6 drives the association signal (rs201622589, MAF~0.1%, odds ratio = 10.13, p-value = 0.042) and results in complete loss of secretion in cells. Further analysis including additional case-control studies and population controls (N = 260,642) did not support association of this variant with obesity (odds ratio = 2.34, p-value = 2.59 × 10−3), highlighting the challenges of testing rare variant associations and the need for very large sample sizes.
    [Show full text]
  • Ciliopathies Gene Panel
    Ciliopathies Gene Panel Contact details Introduction Molecular Genetics Service The ciliopathies are a heterogeneous group of conditions with considerable phenotypic overlap. Level 6, Barclay House These inherited diseases are caused by defects in cilia; hair-like projections present on most 37 Queen Square cells, with roles in key human developmental processes via their motility and signalling functions. Ciliopathies are often lethal and multiple organ systems are affected. Ciliopathies are London, WC1N 3BH united in being genetically heterogeneous conditions and the different subtypes can share T +44 (0) 20 7762 6888 many clinical features, predominantly cystic kidney disease, but also retinal, respiratory, F +44 (0) 20 7813 8578 skeletal, hepatic and neurological defects in addition to metabolic defects, laterality defects and polydactyly. Their clinical variability can make ciliopathies hard to recognise, reflecting the ubiquity of cilia. Gene panels currently offer the best solution to tackling mutational analysis of Samples required genetically heterogeneous conditions such as the ciliopathies. Ciliopathies affect approximately 5ml venous blood in plastic EDTA 1:2,000 births. bottles (>1ml from neonates) Ciliopathies are generally inherited in an autosomal recessive manner, with some autosomal Prenatal testing must be arranged dominant and X-linked exceptions. in advance, through a Clinical Genetics department if possible. Referrals Amniotic fluid or CV samples Patients presenting with a ciliopathy; due to the phenotypic variability this could be a diverse set should be sent to Cytogenetics for of features. For guidance contact the laboratory or Dr Hannah Mitchison dissecting and culturing, with ([email protected]) / Prof Phil Beales ([email protected]) instructions to forward the sample to the Regional Molecular Genetics Referrals will be accepted from clinical geneticists and consultants in nephrology, metabolic, laboratory for analysis respiratory and retinal diseases.
    [Show full text]
  • GENETIC STUDY of RENAL DISEASES (Nephroref Global®) by MASSIVE SEQUENCING (NGS)
    Pablo Iglesias, 57 – Polígono Gran Via Sur 08908 L'Hospitalet de Llobregat (Barcelona) Tel. 932 593 700 – Fax. 932 845 000 GENETIC STUDY OF RENAL DISEASES (NephroRef Global®) BY MASSIVE SEQUENCING (NGS) Request No.: 000 Client: - Analysis code: 55580 Patient Name: xxx Date of Birth: N/A Patient Ref.: xxx Gender: Female Sample Type: Blood EDTA Sample Arrival Date: DD/MM/AAAA Date of Result: DD/MM/AAAA Clinical information: A 9-year-old patient with a nephrotic syndrome without response to corticosteroid therapy. She has nephrotic-range proteinuria with microhematuria, hypoalbuminemia with hypercholesterolemia and normal glomerular filtration. Paternal aunt with cortico-resistant nephrotic syndrome with evolution to end-stage renal failure that required renal transplantation at age 13. RESULT AND INTERPRETATION The presence of a heterozygous likely pathogenic variant has been identified. In addition, the presence of a heterozygous variant of uncertain clinical significance (VUS) has been identified.(See Interpretation and recommendations) The complete list of studied genes is available in Annex 1. (Methodology) The list of reported genes and coverage details is available in Table 1. (Methodology) Gene Variant* Zygosity Inheritance pattern Classification^ NPHS2 NM_014625.3: c.842A>C Heterozygosis Autosomal Recessive Likely Patogénica p.(Glu281Ala) INF2 NM_022489.3: c.67T>A Heterozygosis Autosomal Recessive VUS p.(Ser23Thr) * Nomenclature according to HGVS v15.11 ^ Based on the recommendations of the American College of Medical Genetics and Genomics (ACMG) Physician, technical specialist responsible for Clinical Analysis: Jaime Torrents Pont. The results relate to samples received and analysed. This report may not be reproduced in part without permission. This document is addressed to the addressee and contains confidential information.
    [Show full text]
  • European School of Genetic Medicine Eye Genetics
    European School of Genetic Medicine th 4 Course in Eye Genetics Bertinoro, Italy, September 27-29, 2015 Bertinoro University Residential Centre Via Frangipane, 6 – Bertinoro www.ceub.it Course Directors: R. Allikmets (Columbia University, New York) A. Ciardella (U.O. Oftalmologia, Policlinico Sant’ Orsola, Bologna) B. P. Leroy (Ghent University, Ghent) M. Seri (U.O Genetica Medica, Bologna). th 4 Course in Eye Genetics Bertinoro, Italy, September 27-29, 2015 CONTENTS PROGRAMME 3 ABSTRACTS OF LECTURES 6 ABSTRACTS OF STUDENTS POSTERS 26 STUDENTS WHO IS WHO 39 FACULTY WHO IS WHO 41 2 4TH COURSE IN EYE GENETICS Bertinoro University Residential Centre Bertinoro, Italy, September 27-29, 2015 Arrival day: Saturday, September 26th September 27 8:30 - 8:40 Welcome 8:40 - 9:10 History of Medical Genetics Giovanni Romeo 9:15 - 10:00 2 parallel talks: (40 min + 5 min discussion) Garrison Room 1. Overview of clinical ophthalmology for basic scientists Antonio Ciardella Jacopo da Bertinoro Room 2. Overview of basic medical genetics for ophthalmologists Bart Leroy 10:05 - 11:35 2 talks (40 min + 5 min discussion) 3. Stargardt disease, the complex simple retinal disorder Rando Allikmets 4. Overview of inherited corneal disorders Graeme Black 11:35 - 12:00 Break 12:00 - 13:30 2 talks (40 min + 5 min discussion) 1. Molecular basis of non-syndromic and syndromic retinal and vitreoretinal diseases Wolfgang Berger 2. Introduction to next-generation sequencing for eye diseases Lonneke Haer-Wigman 13:30 - 14:30 Lunch 14:30 - 16:15 3 parallel workshops
    [Show full text]
  • Ciliopathies Gene Panel
    Ciliopathies Gene Panel Contact details Introduction Regional Genetics Service The ciliopathies are a heterogeneous group of conditions with considerable phenotypic overlap. Levels 4-6, Barclay House These inherited diseases are caused by defects in cilia; hair-like projections present on most 37 Queen Square cells, with roles in key human developmental processes via their motility and signalling functions. Ciliopathies are often lethal and multiple organ systems are affected. Ciliopathies are London, WC1N 3BH united in being genetically heterogeneous conditions and the different subtypes can share T +44 (0) 20 7762 6888 many clinical features, predominantly cystic kidney disease, but also retinal, respiratory, F +44 (0) 20 7813 8578 skeletal, hepatic and neurological defects in addition to metabolic defects, laterality defects and polydactyly. Their clinical variability can make ciliopathies hard to recognise, reflecting the ubiquity of cilia. Gene panels currently offer the best solution to tackling analysis of genetically Samples required heterogeneous conditions such as the ciliopathies. Ciliopathies affect approximately 1:2,000 5ml venous blood in plastic EDTA births. bottles (>1ml from neonates) Ciliopathies are generally inherited in an autosomal recessive manner, with some autosomal Prenatal testing must be arranged dominant and X-linked exceptions. in advance, through a Clinical Genetics department if possible. Referrals Amniotic fluid or CV samples Patients presenting with a ciliopathy; due to the phenotypic variability this could be a diverse set should be sent to Cytogenetics for of features. For guidance contact the laboratory or Dr Hannah Mitchison dissecting and culturing, with ([email protected]) / Prof Phil Beales ([email protected]) instructions to forward the sample to the Regional Molecular Genetics Referrals will be accepted from clinical geneticists and consultants in nephrology, metabolic, laboratory for analysis respiratory and retinal diseases.
    [Show full text]
  • Loss of C. Elegans BBS-7 and BBS-8 Protein Function Results in Cilia Defects and Compromised Intraflagellar Transport
    Downloaded from genesdev.cshlp.org on September 29, 2021 - Published by Cold Spring Harbor Laboratory Press Loss of C. elegans BBS-7 and BBS-8 protein function results in cilia defects and compromised intraflagellar transport Oliver E. Blacque,1 Michael J. Reardon,2 Chunmei Li,1 Jonathan McCarthy,1 Moe R. Mahjoub,3 Stephen J. Ansley,4 Jose L. Badano,4 Allan K. Mah,1 Philip L. Beales,6 William S. Davidson,1 Robert C. Johnsen,1 Mark Audeh,2 Ronald H.A. Plasterk,7 David L. Baillie,1 Nicholas Katsanis,4,5 Lynne M. Quarmby,3 Stephen R. Wicks,2 and Michel R. Leroux1,8 1Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, B.C. V5A 1S6, Canada; 2Department of Biology, Boston College, Chestnut Hill, Massachusetts 02467, USA; 3Department of Biological Sciences, Simon Fraser University, Burnaby, B.C. V5A 1S6, Canada; 4Institute of Genetic Medicine and 5Wilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland 21287, USA; 6Molecular Medicine Unit, Institute of Child Health, University College London, London WC1 1EH, UK; 7The Hubrecht Laboratory, Netherlands Institute of Developmental Biology, Uppsalalaan 8, 3584CT, Utrecht, The Netherlands Bardet-Biedl syndrome (BBS) is a genetically heterogeneous developmental disorder whose molecular basis is largely unknown. Here, we show that mutations in the Caenorhabditis elegans bbs-7 and bbs-8 genes cause structural and functional defects in cilia. C. elegans BBS proteins localize predominantly at the base of cilia, and like proteins involved in intraflagellar transport (IFT), a process necessary for cilia biogenesis and maintenance, move bidirectionally along the ciliary axoneme. Importantly, we demonstrate that BBS-7 and BBS-8 are required for the normal localization/motility of the IFT proteins OSM-5/Polaris and CHE-11, and to a notably lesser extent, CHE-2.
    [Show full text]
  • Treatment Potential for LCA5-Associated Leber Congenital Amaurosis
    Retina Treatment Potential for LCA5-Associated Leber Congenital Amaurosis Katherine E. Uyhazi,1,2 Puya Aravand,1 Brent A. Bell,1 Zhangyong Wei,1 Lanfranco Leo,1 Leona W. Serrano,2 Denise J. Pearson,1,2 Ivan Shpylchak,1 Jennifer Pham,1 Vidyullatha Vasireddy,1 Jean Bennett,1 and Tomas S. Aleman1,2 1Center for Advanced Retinal and Ocular Therapeutics (CAROT) and F.M. Kirby Center for Molecular Ophthalmology, University of Pennsylvania, Philadelphia, PA, USA 2Scheie Eye Institute at The Perelman Center for Advanced Medicine, University of Pennsylvania, Philadelphia, PA, USA Correspondence: Tomas S. Aleman, PURPOSE. To determine the therapeutic window for gene augmentation for Leber congen- Perelman Center for Advanced ital amaurosis (LCA) associated with mutations in LCA5. Medicine, University of Pennsylvania, 3400 Civic Center METHODS. Five patients (ages 6–31) with LCA and biallelic LCA5 mutations underwent Blvd, Philadelphia, PA 19104, USA; an ophthalmic examination including optical coherence tomography (SD-OCT), full-field [email protected]. stimulus testing (FST), and pupillometry. The time course of photoreceptor degeneration in the Lca5gt/gt mouse model and the efficacy of subretinal gene augmentation therapy Received: November 19, 2019 with AAV8-hLCA5 delivered at postnatal day 5 (P5) (early, n = 11 eyes), P15 (mid, n = 14), Accepted: March 16, 2020 = Published: May 19, 2020 and P30 (late, n 13) were assessed using SD-OCT, histologic study, electroretinography (ERG), and pupillometry. Comparisons were made with the human disease. Citation: Uyhazi KE, Aravand P, Bell BA, et al. Treatment potential for RESULTS. Patients with LCA5-LCA showed a maculopathy with detectable outer nuclear LCA5-associated Leber congenital layer (ONL) in the pericentral retina and at least 4 log units of dark-adapted sensitivity amaurosis.
    [Show full text]
  • Evidence of Oligogenic Inheritance in Nephronophthisis
    JASN Express. Published on September 12, 2007 as doi: 10.1681/ASN.2007020243 CLINICAL RESEARCH www.jasn.org Evidence of Oligogenic Inheritance in Nephronophthisis Julia Hoefele,*† Matthias T.F. Wolf,* John F. O’Toole,* Edgar A. Otto,* Ulla Schultheiss,* Georges Deˆschenes,‡ Massimo Attanasio,* Boris Utsch,* Corinne Antignac,§ and ʈ Friedhelm Hildebrandt* ʈ Departments of *Pediatrics and Human Genetics, University of Michigan, Ann Arbor, Michigan; †Department of Pediatrics, University Children’s Hospital, University of Munich, Munich, Germany; and ‡Hoˆpital Robert Debre´, Pediatric Nephrology, AP-HP, and §INSERM, U574, Universite´ Paris Descartes, Faculte de Me´dicine Rene´ Descartes, and Hoˆpital Necker-Enfants Malades, AP-HP, Department of Genetics, Paris, France ABSTRACT Nephronophthisis is a recessive cystic renal disease that leads to end-stage renal failure in the first two decades of life. Twenty-five percent of nephronophthisis cases are caused by large homozygous deletions of NPHP1, but six genes responsible for nephronophthisis have been identified. Because oligogenic inheritance has been described for the related Bardet-Biedl syndrome, we evaluated whether mutations in more than one gene may also be detected in cases of nephronophthisis. Because the nephrocystins 1 to 4 are known to interact, we examined patients with nephronophthisis from 94 different families and sequenced all exons of the NPHP1, NPHP2, NPHP3, and NPHP4 genes. In our previous studies involving 44 families, we detected two mutations in one of the NPHP1–4 genes. Here, we detected in six families two mutations in either NPHP1, NPHP3, or NPHP4, and identified a third mutation in one of the other NPHP genes. Furthermore, we found possible digenic disease by detecting one individual who carried one mutation in NPHP2 and a second mutation in NPHP3.
    [Show full text]
  • Weight Patterns and Genetics in a Rare Obesity Syndrome
    Received: 22 May 2020 Accepted: 30 June 2020 DOI: 10.1111/ijpo.12703 ORIGINAL RESEARCH Bardet-Biedl syndrome: Weight patterns and genetics in a rare obesity syndrome Jeremy Pomeroy1 | Anthony D. Krentz2 | Jesse G. Richardson1 | Richard L. Berg1 | Jeffrey J. VanWormer1 | Robert M. Haws1,3 1Clinical Research Center, Marshfield Clinic Research Institute, Marshfield, Wisconsin Summary 2Prevention Genetics, Marshfield, Wisconsin Background: Bardet-Biedl syndrome (BBS) is a rare genetic disorder that severely 3Department of Pediatrics, Marshfield Clinic inhibits primary cilia function. BBS is typified by obesity in adulthood, but pediatric Health System, Marshfield, Wisconsin weight patterns, and thus optimal periods of intervention, are poorly understood. Correspondence Objectives: To examine body mass differences by age, gender, and genotype in chil- Jeremy Pomeroy, Marshfield Clinic Research Institute, 1000 North Oak Ave, Marshfield, WI dren and adolescents with BBS. 54449. Methods: We utilized the largest international registry of BBS phenotypes. Anthro- Email: [email protected] pometric and genetic data were obtained from medical records or participant/family interviews. Participants were stratified by age and sex categories. Genotype and obe- sity phenotype were investigated in a subset of participants with available data. Results: Height and weight measurements were available for 552 unique individuals with BBS. The majority of birth weights were in the normal range, but rates of over- weight or obesity rapidly increased in early childhood, exceeding 90% after age 5. Weight z-scores in groups >2 years were above 2.0, while height z-scores approached 1.0, but were close to 0.0 in adolescents. Relative to those with the BBS10 genotype, the BBS1 cohort had a lower BMI z-score in the 2-5 and 6-11 age groups, with similar BMI z-scores thereafter.
    [Show full text]
  • [Frontiers in Bioscience 13, 2633-2652, January 1, 2008] 2633 Intraflagellar Transport: from Molecular Characterisation to Mech
    [Frontiers in Bioscience 13, 2633-2652, January 1, 2008] Intraflagellar transport: from molecular characterisation to mechanism Oliver E. Blacque1, Sebiha Cevik1, Oktay Ismail Kaplan1 1School of Biomolecular and Biomedical Science, UCD Conway Institute, University College Dublin, Belfield, Dublin 4, Ireland TABLE OF CONTENTS 1. Abstract 2. Introduction 2.1. Scope of Review 2.2. Overview of cilia and flagella 2.2.1. Two classes of cilia: motile and non-motile 2.2.2. Cilium structure 2.2.3. The ‘ciliome’ 2.3. Discovery of IFT 2.4. IFT in outline 3. The IFT machinery: lessons from unicellular chlamydomonas 3.1. Kinesin 2: the anterograde IFT motor 3.2. IFT-dynein: the retrograde motor 3.3. The IFT particle 3.3.1. IFT particle complexes A and B are functionally distinct 4. IFT in metazoans: the C. elegans model 4.1. Structure/function of C. elegans sensory cilia 4.2. Not one, but two kinesin 2 motors drive C. elegans anterograde IFT 4.3. Novel IFT genes 4.4. Regulation of C. elegans anterograde IFT 4.4.1. bbs gene function coordinates kinesin 2 motor association 4.4.2. dyf-5 regulates the docking/undocking of kinesin 2 motors 5. Vertebrate IFT 5.1. IFT and disease 5.2. Investigation of mammalian IFT 6. IFT and cilium-based signalling 6.1. IFT and sonic hedgehog (Shh) signalling 6.2. IFT and PDGF-AA signalling 6.3. IFT directly mediates Chlamydomonas signalling during mating 7. IFT Cargo 8. IFT and the Cell cycle 9. Mechanism of IFT: a current model 10. Perspective 11.
    [Show full text]